Evidence map›Paper›PMID 31571695›Full record

ArticleMedical history2019

Vaccine Development and Collaborations: Lessons from the History of the Meningococcal A Vaccine (1969-73).

Baptiste Baylac-Paouly

Abstract readHistorical Article
In one paragraph

Article in Medical history, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Baptiste Baylac-PaoulyEA 4148 Sciences, Société, Historicité, Éducation et Pratiques (S2HEP), Université de Lyon, Université Claude Bernard Lyon 1, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Based on a wide range of historical sources, including published scientific literature and archives (Institut Mérieux, WHO and IMTSSA), this article examines the history of the development of the meningococcal A vaccine between 1969 and 1973. It explores the social factors of vaccine development including various collaborations, informal discussions, the circulation of products and materials, formal meetings, trials and setbacks to highlight the complex reality of the development, production and use of the vaccine. Inscribed in a 'Golden Age' of vaccine development and production, this episode not only adds to the scholarship on the history of vaccines, which has tended to focus on a narrative of progress, but also considers the sharing of knowledge through collaborations, and the risks involved in the development of a vaccine. Finally, this perspective reveals the uncertainties and difficulties underlying the production of an effective vaccine.

Indexed as

History, 20th CenturyHumansInternational CooperationMeningitis, MeningococcalMeningococcal VaccinesPolysaccharides, BacterialWorld Health Organizationmeningococcal group A polysaccharideMeningococcal VaccinesPolysaccharides, BacterialAfricaCerebrospinal meningitis ACollaborationsInstitut MérieuxMeningococcal vaccineWorld Health Organization

Identifiers

PMID31571695
PMCPMC6733771

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.